Melanoma of the head and neck

Current Treatment Options in Oncology

Volumn 6, Issue 1, 2005, Pages 19-30

  Day, Terry A ^a   Hornig, Joshua D ^b   Sharma, Anand K ^b   Brescia, Frank ^b   Gillespie, M Boyd ^b   Lathers, Deanne ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DINITROPHENOL; ALPHA2B INTERFERON; CANCER VACCINE; CANVAXIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; HAPTEN; INTERLEUKIN 2; MELANOMA VACCINE; PIOGLITAZONE; PLACEBO; ROFECOXIB; TEMOZOLOMIDE; TROFOSFAMIDE; TUMOR CELL VACCINE; VACCINE; VINBLASTINE;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BLEEDING; BLOOD VESSEL INJURY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHYLE; CLINICAL TRIAL; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; CRANIAL NERVE INJURY; DELAYED HYPERSENSITIVITY; DIET RESTRICTION; DISEASE COURSE; DRUG MEGADOSE; DYSPLASTIC NEVUS; EVIDENCE BASED MEDICINE; FACIAL NERVE PARALYSIS; FOLLOW UP; GENE TARGETING; GENETIC IDENTIFICATION; GENETIC SCREENING; HEAD AND NECK TUMOR; HEMATOMA; HEREDITY; HUMAN; LIFESTYLE; LOW DRUG DOSE; LYMPHOSCINTIGRAPHY; MELANOMA; METASTASIS; NECK DISSECTION; NERVE INJURY; PARESTHESIA; PAROTIDECTOMY; PROGNOSIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RECURRENCE RISK; REVIEW; RISK FACTOR; SCAR; SENTINEL LYMPH NODE BIOPSY; SUN EXPOSURE; SURGICAL TECHNIQUE; SWEAT GLAND DISEASE; ULCER;

EID: 13544268705     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-005-0010-5     Document Type: Review

References (70)

1. Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics. CA Cancer J Clin 2004, 54:8-29.
2. Greene FL, Page DL, Fleming ID, et al.: Cancer Staging Handbook. 6th ed. New York: Springer-Verlag; 2002.
3. Balch CM, et al.: An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 2004. 54(3): 31-149; quiz 182-184.
4. Balch CM, et al.: Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001, 19(16 : 622-3634.
5. Bulliard JL: Site-specific risk of cutaneous malignant melanoma and pattern of sun exposure in New Zealand. Int J Cancer 2000, 85:627-632.
6. Naldi L, Lorenzo Imberti G, Parazzini F, et al.: Pigmentary traits, modalities of sun reaction, history of sunburns, and melanocytic nevi as risk factors for cutaneous malignant melanoma in the Italian population: results of a collaborative case-control study. Cancer 2000, 88:2703-2710.
7. Rafnsson V, Hrafnkelsson J, Tulinius H, et al.: Risk factors for malignant melanoma in an Icelandic population sample. Prev Med 2004, 39:247-252.
8. Bakos L, Wagner M, Bakos RM, et al.: Sunburn, sunscreens, and phenotypes: some risk factors for cutaneous melanoma in southern Brazil. Int J Dermatol 2002, 41:557-562.
9. Fargnoli MC, Piccolo D, Altobelli E, et al.: Constitutional and environmental risk factors for cutaneous melanoma in an Italian population. A case-control study. Melanoma Res 2004, 14:151-157.
10. Youl P, Aitken J, Hayward N, et al.: Melanoma in adolescents: a case-control study of risk factors in Queensland, Australia. Int J Cancer 2002, 98:92-98.
11. Bulliard JL, Cox B, Semenciw R: Trends by anatomic site in the incidence of cutaneous malignant melanoma in Canada, 1969-93. Cancer Causes Control 1999, 10:407-416.
12. Nashan D, Kocer B, Schiller M, et al.: Significant risk of a second melanoma in patients with a history of melanoma but no further predisposing factors. Dermatology 2003, 206:76-77.
13. Hussein MR: Genetic pathways to melanoma tumorigenesis. J Clin Pathol 2004, 57:797-801.
14. Gillgren P, Brattstrom G, Frisell J, et al.: Body site of cutaneous malignant melanoma - a study on patients with hereditary and multiple sporadic tumours. Melanoma Res 2003, 13:279-286.
15. Hansen CB, Wadge LM, Lowstuter K, et al.: Clinical germline genetic testing for melanoma. Lancet 2004, 5: 14-319.
16. Hemo Y, Gutman M, Klausner JM: Anatomic site of primary melanoma is associated with depth of invasion. Arch Surg 1999, 134:148-150.
17. Morton DL, Hsueh EC, Essner R, et al.: Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 2002, 236: 38-448.
18. Andersson AP, Gottlieb J, Drzewiecki KT, et al.: Skin melanoma of the head and neck. Prognostic factors and recurrence-free survival in 512 patients. Cancer 1992, 69: 153-1156.
19. Cascinelli N, Santinami M, Maurichi A, et al.: World Health Organization experience in the treatment of melanoma. Surg Clin North Am 2003, 83:405-416.
20. Bienert TN, Trotter MJ, Arlette JP: Treatment of cutaneous melanoma of the face by Mohs micrographic surgery. J Cutan Med Surg 2003, 7:25-30.
21. Cascinelli N: Margin of resection in the management of primary melanoma. Semin Surg Oncol 1998, 14:272-275.
22. Piepkorn M: Melanoma resection margin recommendations, unconventionally based on available facts. Semin Diagn Pathol 1998, 15:230-234.
23. Pathak I, O'Brien CJ, Petersen-Schaeffer K, et al.: Do nodal metastases from cutaneous melanoma of the head and neck follow a clinically predictable pattern? Head Neck 2001, 23: 85-790.
24. Gershenwald JE, Thompson W, Mansfield PF, et al.: Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999, 17:976-983.
25. Medina-Franco H, Beenken SW, Heslin MJ, Urist MM: Sentinel node biopsy for cutaneous melanoma in the head and neck. Ann Surg Oncol 2001, 8:716-719.
26. O'Brien CJ, Coates AS, Petersen-Schaefer K, et al.: Experience with 998 cutaneous melanomas of the head and neck over 30 years. Am J Surg 1991, 162:310-314.
27. Smithers BM, McLeod GR, Little JH: Desmoplastic melanoma: patterns of recurrence. World J Surg 1992, 16:186-190.
28. Byers RM: The role of modified neck dissection in the treatment of cutaneous melanoma of the head and neck. Arch Surg 1986, 121:1338-1341.
29. Bonnen MD, Ballo MT, Myers JN, et al.: Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer 2004, 100:383-389.
30. Ang KK, Peters LJ, Weber RS, et al.: Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys 1994, 30:795-798.
31. Ballo MT, Ang KK: Radiation therapy for malignant melanoma. Surg Clin North Am 2003, 83:323-342.
32. Pidhorecky I, Lee RJ, Proulx G, et al.: Risk factors for nodal recurrence after lymphadenectomy for melanoma. Ann Surg Oncol 2001, 8:109-115.
33. O'Brien CJ, Petersen-Schaefer K, Stevens GN, et al.: Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma. Head Neck 1997, 19:589-594.
34. Harwood AR: Conventional fractionated radiotherapy for 51 patients with lentigo maligna and lentigo maligna melanoma. Int J Radiat Oncol Biol Phys 1983, 9:1019-1021.
35. Ballo MT, Bonnen MD, Garden AS, et al.: Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer 2003, 97:1789-1796.
36. Storper IS, Lee SP, Abemayor E, Juillard G: The role of radiation therapy in the treatment of head and neck cutaneous melanoma. Am J Otolaryngol 1993, 14:426-431.
37. Cooper JS, Chang WS, Oratz R, et al.: Elective radiation therapy for high-risk malignant melanomas. Cancer 2001, 7:498-502.
38. Veness: Cutaneous head and neck squamous cell carcinoma metastatic to cervical lymph nodes (non-parotid): a better outcome with surgery and adjuvant radiotherapy. Laryngoscope 2003, 113: 827-1833.
39. Lee RJ, Gibbs JF, Proulx GM, et al.: Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2000, 46: 67-474.
40. Rofstad EK: Radiation sensitivity in vitro of primary tumors and metastatic lesions of malignant melanoma. Cancer Res 1992, 52:4453-4457.
41. Konefal JB, Emami B, Pilepich MV: Malignant melanoma: analysis of dose fractionation in radiation therapy. Radiology 1987, 164:607-610.
42. Overgaard J, Overgaard M, Hansen PV, von der Maase H, et al.: Some factors of importance in the radiation treatment of malignant melanoma. Radiother Oncol 1986, 5:183-192.
43. Pyrhonen SO, Kajanti MJ: The use of large fractions in radiotherapy for malignant melanoma. Radiother Oncol 1992, 24:195-197.
44. Strauss A, Dritschilo A, Nathanson L, Piro AJ, et al.: Radiation therapy of malignant melanomas: an evaluation of clinically used fractionation schemes. Cancer 1981, 47:1262-1266.
45. Sause WT, Cooper JS, Rush S, et al.: Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 1991, 20:429-432.
46. Mori Y, Kondziolka D, Flickringer JC, et al.: Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys 1998, 42:581-589.
47. Mansfield PF, Lee JE, Balch CM: Cutaneous melanoma: current practice and surgical controversies. Curr Probl Surg 1994, 31:253-374.
48. Burmeister BH, Smithers BM, Davis S, et al.: Radiation therapy following nodal surgery for melanoma: an analysis of late toxicity. ANZ J Surg 2002, 72:344-348.
49. Agarwala SS, Kirkwood JM, Gore M, et al.: Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004, 22: 101-2107.
50. Awada A, Gil T, Sales F, Dubuisson M, et al.: Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers. Anti-cancer Drugs 2004, 15:499-502.
51. Danson S, Lorigan P, Arance A, et al.: Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol 2003, 21:2551-2557.
52. de Gast GC, Batchelor D, Kersten MJ, et al.: Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN-α in patients with metastatic melanoma. Br J Cancer 2003, 88:175-180.
53. Hwu WJ, Krown SE, Menell JH, et al.: Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 2003, 21:3351-3356.
54. Richtig E, Hofmann-Wellenhof R, Pehamberger H, et al.: Temozolomide and interferon-α 2b in metastatic melanoma stage IV. Br J Dermatol 2004, 151:91-98.
55. Ridolfi R, Romanini A, Sileni VC, et al.: Temozolomide and interferon-α in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup. Melanoma Res 2004, 14: 95-299.
56. Agarwala, S.S. and J.M. Kirkwood (1996). Interferons in melanoma. Curr Opin Oncol 8:167-174.
57. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. (1996). Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996, 14:7-17.
58. Vlock DR, Andersen J, Kalish LA, et al.: Phase II trial of interferon-alpha in locally recurrent or metastatic squamous cell carcinoma of the head and neck: immunological and clinical correlates. J Immunother Emphasis Tumor Immunol 1996, 19: 33-442.
59. Shaw: Adjuvant immunotherapy for patients with melanoma: are patients with melanoma of the head and neck candidates for this therapy? Head Neck 1996, 19:595-603.
60. Agarwala: Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002, 20:125-133.
61. Atkins MB, Gollob JA, Sosman JA, et al.: A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-α 2B in patients with metastatic melanoma. Clin Cancer Res 2002, 8:3075-3081.
62. Radny P, Caroli UM, Bauer J, et al.: Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 2003, 89:1620-1626.
63. Dillman RO, Soori G, Wiemann MC, et al.: Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-α, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11. Cancer Biother Radiopharm 2000, 15:487-494.
64. Keilholz U, Stoter G, Punt CJ, et al.: Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. Cancer J Sci Am 1997, 3(Suppl 1): 22-28.
65. Signore A, Annovazzi A, Barone R, et al.: 99mTc-Interleukin-2 Scintigraphy as a Potential Tool for Evaluating Tumor-Infiltrating Lymphocytes in Melanoma Lesions: A Validation Study. J Nucl Med 2004, 45:1647-1652.
66. Vilella R, Benitez D, Mila J, et al.: Treatment of patients with progressive unresectable metastatic melanoma with a heterologous polyvalent melanoma whole cell vaccine. Int J Cancer 2003, 106:626-631.
67. Berd D, Sato T, Maguire HC Jr, et al.: Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 2004, 22:403-415.
68. Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, et al.: Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res 2001, 7:1882-1887.
69. Reichle A, Bross K, Vogt T, et al.: Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer 2004. Epub ahead of print.
70. American Joint Committee on Cancer Staging Handbook TNM Classification of Malignant Tumors, 6 edn. Edited by Greene FL, Balch CM, Fleming ID, et al. New York: Springer, 2002:37.